GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

THC Therapeutics THCT · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Net income

−$387,036

FY2015FY2024

Free cash flow

−$85,434

FY2015FY2024

Shareholders' equity

−$3.3m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Gross profit−$1,393—−$12,334—−$20,114−$25,558−$25,434−$10,491——
Operating income−$493,912−$493,912−$1.7m−$939,977−$1.3m−$26.7m−$6.0m−$429,018−$92,848−$273,276
Net income−$387,036−$387,036−$1.5m−$1.9m−$1.9m−$23.6m−$6.1m−$15.6m−$91,998−$284,299
Diluted earnings per share-0.01-0.01-0.05-0.06-0.09-1.60-0.47-1.31-0.17-0.52

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$12,990$12,990$206,901$480,068$85,346$520,022$2.5m$5.2m$175,780$181,953
Cash and short-term investments$10—$32—$43,239$317,551$2,969$187$296$6,469
Total liabilities$3.3m$3.3m$3.3m$3.0m$1.9m$1.3m$581,444$310,889$320,237$459,412
Debt$791,437—$801,028—$430,041$177,553$176,200$82,739$181,115$169,970
Shareholders' equity−$3.3m−$3.3m−$3.1m−$2.5m−$1.8m−$749,406$1.9m$4.8m−$144,457−$277,459
Shares outstanding38m33m33m33m22m15m13m12m1m1m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$85,432−$85,432−$418,917−$388,477−$587,933−$329,803−$190,165−$156,733−$17,318−$11,919
Capital spending−$2—−$3——−$1,195−$532−$20,000−$20,000−$20,000
Free cash flow−$85,434−$85,432−$418,920−$388,477−$587,933−$330,998−$190,697−$176,733−$37,318−$31,919

Latest quarters

By quarter end

Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023Apr 2023Jan 2023
Gross profit−$344−$351—−$351−$340———
Operating income−$379,698−$85,151−$379,698−$54,650−$58,020−$54,651−$58,020−$273,679
Net income$104,622−$571,975$104,622−$32,941$94,355−$32,941$94,355$1.7m
Diluted earnings per share0.00-0.010.00-0.000.00-0.000.000.05
Total assets$11,813$14,819$11,813$12,990$13,346$12,990$13,346$23,030
Cash and short-term investments$849$3,511—$10$15———
Debt$731,789$791,415—$791,437$731,789———
Shareholders' equity−$3.4m−$3.9m−$3.5m−$3.3m−$3.3m−$3.3m−$3.3m−$3.4m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-19.3%-55.0%-1.1%
Net income-41.0%-56.1%-3.9%

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return25614%5620%-95%21671%-35%-39%11%-20%3447%20769%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 10 Dec 2018
  • 14-to-1 reverse split · 10 Jun 2016
  • 5-for-1 split · 13 Mar 2012
  • 1.6-for-1 split · 11 May 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.